Previous 10 | Next 10 |
2024-06-04 09:53:00 ET Novo Nordisk 's (NYSE: NVO) type 2 diabetes drug Ozempic is a sensation, and it's no surprise why. In the first quarter, revenue from Ozempic rose 35% year over year to reach roughly $4.3 billion, and there's no sign of a slowdown in sight. In fact, it's v...
2024-06-02 10:00:00 ET More on Amgen, Structure Therapeutics, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? ...
2024-06-02 09:30:00 ET The pharmaceutical industry isn't the first place investors turn to when looking for high-growth stocks. However, some companies in the field look so promising that they could deliver well-above-average returns through the end of the decade. There are several cand...
2024-06-02 08:25:00 ET Over the last few years, some of the best-performing stocks in the broader healthcare space have been pharmaceutical businesses . A big reason for this is the rise in popularity of weight loss medications. Ozempic and Wegovy are two of the most mainstream trea...
2024-06-01 10:25:00 ET Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are the two most valuable healthcare companies in the world. Combined, they're worth nearly $1.4 trillion. And it's conceivable that their individual valuations could top $1 trillion in the future. How...
2024-06-01 09:00:00 ET More on the markets and the economy Fed may not cut rates in 2024 with inflation's slow downward pace - strategist Investors punished Salesforce after earnings. See other worst post-report reactions PCE April 2024: Personal Spending Data Confir...
2024-05-31 15:00:19 ET More on the markets Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight Hedge funds back at record exposure to Magnificent 7 S&am...
2024-05-30 16:10:00 ET Summary The global market for GLP-1 therapies now looks on pace to top $100 billion. GLP-1 pioneers such as Eli Lilly, Novo Nordisk, could be joined by new players Amgen, Altimmune, Pfizer, Viking, Roche, and privately held Boehringer Ingelheim that have GLP...
2024-05-30 11:22:06 ET More on Eli Lilly, Novo, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Lilly's Retevmo gains appro...
2024-05-29 12:11:20 ET More on Eli Lilly, Novo Nordisk Eli Lilly: Addressing Supply Challenges Should Accelerate Growth SA Asks: Is Eli Lilly or Novo Nordisk a better investment? Novo Nordisk: The Market Is Right, Don't Fight Against It SA Asks: Who...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...